Subscribe
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Issues
2016 Issues
March Vol 9 No 2
TON March 2016 Vol 9 No 2
Counseling, Multiplex Testing May Lower Anxiety in At-Risk Patients with Cancer
By
Wayne Kuznar
Genetic Counseling
TON March 2016 Vol 9 No 2
Multiplex genetic testing in
BRCA1/2
-negative cancer patients with in-person genetic counseling allows informed decision-making while decreasing short-term anxiety, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
Read More ›
All-Oral Combination Therapy Shows Promise in Patients with Transplant-Ineligible, Newly Diagnosed MM
Hematologic Cancers
TON March 2016 Vol 9 No 2
An open-label, randomized, phase 2 study evaluated the all-oral triplet combination of ixazomib (an orally administered proteasome inhibitor) plus cyclophosphamide (at 2 different doses) and low-dose dexamethasone (ICd) as a 12-month induction therapy in previously untreated, transplant-ineligible patients with multiple myeloma (MM).
Read More ›
Bortezomib-Based Combination Overcomes Poor Prognosis in Elderly Patients with Newly Diagnosed MM
Hematologic Cancers
TON March 2016 Vol 9 No 2
Presence of cytogenetic abnormalities (CAs) is considered to be an important prognostic factor in patients with multiple myeloma (MM), with some evidence suggesting that bortezomib-based combinations may overcome the poor prognosis associated with CAs, such as t(4;14), t(14;16), or deletion of 17p (del [17p]).
Read More ›
Final Results of the OPTIM-Imatinib Study in Patients with CP-CML
Hematologic Cancers
TON March 2016 Vol 9 No 2
Imatinib mesylate (IM) at 400 mg/day is the standard of care as first-line therapy in patients with newly diagnosed, chronic-phase chronic myeloid leukemia (CP-CML).
Read More ›
Effect of Nilotinib Treatment Duration on Treatment-Free Remission in Patients with CP-CML
Hematologic Cancers
TON March 2016 Vol 9 No 2
In contrast to current recommendations to continue tyrosine kinase inhibitor therapy indefinitely, emerging evidence indicates that patients with sustained molecular responses (MRs) on imatinib therapy may achieve deep MRs and durable treatment-free remission with nilotinib in patients with chronic-phase chronic myeloid leukemia (CP-CML).
Read More ›
Preparation of Nurses for Cancer Survivorship Care
By
Chase Doyle
Survivorship
TON March 2016 Vol 9 No 2
A collaborative program between Memorial Sloan Kettering Cancer Center in New York, NY, and the City of Hope in Duarte, CA, has helped educate nurses about survivorship care and facilitate their development at their own institutions.
Read More ›
Providing Oncology Care Across the Cancer Care Continuum
By
Chase Doyle
Survivorship
TON March 2016 Vol 9 No 2
A study evaluating a new model for education of primary care nurse practitioners (NPs) in oncology practice has shown effective delivery of essential basic care competencies.
Read More ›
Bridging the Gap Between Pediatric and Adult Care
By
Chase Doyle
Survivorship
TON March 2016 Vol 9 No 2
To decrease barriers to transition for childhood cancer survivors, Children’s Mercy Hospital and the University of Kansas Cancer Center (KUCC), Mercy Hospital, Kansas City, MO, have collaborated to develop the Survivorship Transition Clinic (STC).
Read More ›
PD-1 Inhibitors May Be Effective in Patients with Gastrointestinal Cancers
By
Christine Erickson
Gastrointestinal Cancers
TON March 2016 Vol 9 No 2
Although immunotherapy drugs targeting programmed cell death-1 (PD-1) have proved to be effective in patients with melanoma and lung cancer, new data from 2 recent studies suggest that these drugs may also be effective in patients with certain gastrointestinal cancers.
Read More ›
Noteworthy Numbers: Colorectal Cancer
Noteworthy Numbers
TON March 2016 Vol 9 No 2
The first National Colorectal Cancer Awareness Month was designated in March 2000. Since then, organizations throughout the country have dedicated March to increasing awareness of this disease and encouraging Americans to be screened. Here are some statistics and current information about colorectal cancer (CRC).
Read More ›
Page 2 of 2
1
2
View the Latest Issue of TON
Read Issue
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION